What Is PT-141? Mechanism and Preclinical Research Summary

The short version: What is PT-141 at a glance?

PT-141, chemically designated as Bremelanotide, is a synthetic cyclic heptapeptide derived from Melanotan II. Unlike peripheral vasoactive agents, PT-141 acts directly within the central nervous system as a non-selective agonist at melanocortin receptors, predominantly targeting MC3R and MC4R.

In preclinical settings, researchers evaluate PT-141 for its unique capacity to activate central neurochemical pathways associated with sexual behavior and autonomic response without inducing vascular smooth muscle relaxation.

When sourcing this agent for laboratory protocols, principal investigators require strict analytical verification. Every lot must present high chromatographic purity, clear mass spectrometry identification, and verified endotoxin limits before entering in vitro or animal models.

You can review our complete selection of analytical-grade compounds in the catalog of research peptides or inspect specific technical specifications on our dedicated PT-141 research profile.

What is the chemical structure and origin of PT-141?

PT-141 was originally developed through structural modification of the synthetic peptide Melanotan II (MT-2). Synthetic chemists isolated the active metabolite of MT-2 and removed the C-terminal amide group, producing a cyclic peptide sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. This specific cyclic configuration grants enhanced enzymatic stability in aqueous buffer systems compared to linear peptide chains.

With a molecular formula of C50H68N14O10 and a molecular weight of approximately 1025.2 g/mol, PT-141 exhibits distinct physical and chemical characteristics. The intramolecular lactam bridge between the aspartic acid and lysine residues stabilizes the secondary conformation required for high-affinity binding to central melanocortin receptors.

Because structural integrity directly impacts binding kinetics during competitive binding assays, researchers must source material synthesized via solid-phase peptide synthesis (SPPS) that undergoes rigorous post-cleavage purification. Unpurified synthetic artifacts or truncated sequences can yield false-negative receptor binding assays.

How does PT-141 work? Receptor targets and signaling pathways

PT-141 operates primarily as a full agonist at central melanocortin receptors. Preclinical receptor-binding profiles demonstrate that PT-141 exhibits significant binding affinity for melanocortin receptor subtypes MC1R, MC3R, MC4R, and MC5R, while exhibiting minimal interaction with MC2R (the adrenal ACTH receptor).

The primary biological responses observed in rodent models are attributed to the activation of central MC4R and MC3R networks located within the hypothalamus, specifically inside the paraventricular nucleus (PVN) and the medial preoptic area (mPOA). Binding to these central receptors stimulates downstream neurochemical signaling, including the downstream release of dopamine in the nucleus accumbens.

Because PT-141 functions via central neurogenic pathways rather than localized nitric oxide elevation or phosphodiesterase type 5 (PDE5) inhibition, it represents a novel molecular tool for investigating central regulation of autonomic and behavioral responses in animal models.

In which preclinical research models is PT-141 studied?

In academic and pharmaceutical laboratory settings, PT-141 is actively investigated across several established rodent and non-human primate experimental models. Researchers utilize the compound to map central neural pathways involved in behavioral motivation and autonomic tone.

Key experimental frameworks incorporating PT-141 include:

1. Central Nervous System Behavioral Assays: Rodent models measuring appetitive and consummatory sexual behaviors, lordosis quotient, and proceptivity metrics following central or systemic administration.

2. Autonomic Neural Pathway Mapping: Studies evaluating c-Fos expression and neurochemical flux within the paraventricular nucleus and ventral tegmental area to trace melanocortinergic projections.

3. Comparative Receptor Profiling: In vitro cell-line assays (CHO or HEK293 cells expressing human recombinant MC3R and MC4R) assessing cAMP accumulation, beta-arrestin recruitment, and receptor desensitization kinetics.

4. Metabolic and Thermoregulatory Investigations: Exploration of secondary melanocortin pathways controlling energy expenditure, satiety signaling, and sympathetic nervous system outflow.

How does PT-141 compare to related melanocortin peptides?

To select the correct compound for a specific experimental design, investigators must understand how PT-141 differs structurally and functionally from related melanocortin receptor ligands. The melanocortin peptide family includes endogenous alpha-MSH as well as synthetic derivatives like Melanotan I and Melanotan II.

Melanotan I (Afamelanotide) is a linear peptide engineered primarily as a selective MC1R agonist, promoting melanogenesis in cutaneous tissue with limited central nervous system penetrance. Laboratories focused on pigmentation pathways typically reference our Melanotan I research overview.

Melanotan II (MT-2) is a cyclic non-selective melanocortin agonist that crosses the blood-brain barrier and activates MC1R, MC3R, MC4R, and MC5R. While MT-2 triggers both central behavioral responses and peripheral melanogenesis, PT-141 is a hydroxylated metabolite derivative designed to reduce MC1R-driven pigmentation activity while preserving central MC3R/MC4R potency. Researchers evaluating dual-pathway ligands can inspect Melanotan II technical documentation for comparative data.

When your experimental protocol demands isolated central melanocortin signaling without confounding cutaneous pigmentary shifts, scientists routinely buy PT-141 10mg vials for consistent binding kinetics.

What criteria should laboratories specify when sourcing PT-141?

Acquiring reliable, reproducible data in peptide research requires strict raw-material specifications. Minor impurities, residual trifluoroacetic acid (TFA), or bacterial endotoxins can alter cellular signaling, induce cytotoxicity, or skew binding curves in sensitive assays.

When preparing purchase requisitions for PT-141, research managers and principal investigators should require vendors to document the following parameters:

1. Purity via Reverse-Phase HPLC: Material must demonstrate ≥98.0% purity, with individual peak integration showing no single impurity greater than 0.5%.

2. Exact Mass Verification via LC-MS: Electrospray ionization mass spectrometry (ESI-MS) must confirm the predicted molecular mass (1025.2 Da) without residual synthesis fragments.

3. Endotoxin Quantitation: Bacterial endotoxin levels measured by Limulus Amebocyte Lysate (LAL) testing must remain strictly below 0.1 EU/mg to prevent immune activation in cell cultures or animal subjects.

4. Trifluoroacetate (TFA) Counterion Content: Residual TFA from RP-HPLC mobile phases should be quantified or exchanged to acetate/chloride forms when conducting sensitive cell-based experiments.

5. Net Peptide Content: Total nitrogen or amino acid analysis (AAA) should be provided to differentiate dry mass weight from actual peptide content, ensuring accurate molar concentration calculations.

Supplier evaluation criteria: How PX1 Research compares

Selecting a verified research supplier ensures that experimental variables remain strictly controlled. The matrix below outlines how PX1 Research meets rigorous analytical criteria compared to standard retail peptide vendors.

Criteria | Standard Retail Vendor | PX1 Research Standard Sourcing & Synthesis | Unverified overseas manufacturing | Verified USA synthesis protocols Analytical Testing | Generic or shared batch COAs | Independent 3rd-party HPLC/MS per specific lot Endotoxin Data | Typically unmeasured or omitted | Quantitative LAL assay verified (<0.1 EU/mg) Lot Traceability | Limited or missing batch numbers | Full chain-of-custody lot coding on every vial Fulfillment Speed | Unpredictable international shipping | Same-day dispatch (M–F) from CA & AZ hubs Technical Support | Automated or non-technical response | Direct access to PhD-level technical specialists

To maintain complete transparency across all laboratory procurement, PX1 Research archives every batch analysis in our publicly accessible PX1 research library.

Red flags when evaluating research peptide vendors

The market for research peptides contains numerous suppliers that lack adequate quality control systems. Utilizing compromised peptides introduces unquantifiable variables that waste research budgets and invalidate publication data.

Watch for these critical vendor red flags before placing an order:

• Shared or Photolithographed COAs: Vendor displays a single static COA image across multiple product pages or uses generic reports where the lot number does not match the physical vial received.

• Absence of Mass Spectrometry Data: Vendor offers HPLC purity reports without accompanying LC-MS spectra, leaving open the possibility of co-eluting isomeric impurities or incorrect peptide sequences.

• No Endotoxin or Bioburden Screening: Lack of LAL assay data poses severe risks of endotoxin contamination, which causes non-specific inflammatory signaling in cell culture assays.

• Claims of Medical Efficacy or Dosing Advice: Vendors offering clinical dosing schedules, human administration protocols, or therapeutic claims operate outside legitimate scientific research standards.

• Lack of Physical Domestic Logistics: Vendors shipping from unknown offshore locations without temperature-controlled transit capabilities risk heat-induced peptide degradation prior to arrival.

Handling, reconstitution, and storage standards for in vitro studies

PT-141 is supplied as a lyophilized (freeze-dried) powder under inert argon gas to preserve structural stability during transit. Proper laboratory handling protocols must be observed upon receipt to prevent thermal or mechanical degradation.

Upon delivery, unopened lyophilized vials should be stored at -20°C for short-term projects or -80°C for long-term preservation. Exposure to ambient room temperature during typical shipping durations does not compromise peptide stability, provided the vial remains sealed and dry.

When reconstituting PT-141 for laboratory protocols, researchers should allow the vial to equilibrate to room temperature before adding sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline. Reconstitution should be performed by gently introducing the solvent along the glass vial wall, followed by light swirling. Swirling should be gentle; aggressive vortexing can cause mechanical shearing of the cyclic peptide backbone.

Once reconstituted in aqueous solution, PT-141 should be aliquoted into sterile polypropylene microcentrifuge tubes to avoid repeated freeze-thaw cycles and maintained at 2°C to 8°C for up to 30 days. For bulk requirements or high-throughput screening projects, laboratories can submit bulk peptide inquiries to obtain custom packaging formats.

Ordering PT-141 from PX1 Research

PX1 Research is dedicated to supporting academic, biotechnology, and institutional researchers with verified, high-purity reagents. When you purchase from PX1 Research, your order is backed by complete analytical documentation and rapid domestic fulfillment.

Each shipment includes vacuum-sealed, tamper-evident lyophilized vials accompanied by physical batch documentation. Our California and Arizona distribution centers process and ship orders same-day when placed before 3:00 PM EST, Monday through Friday, ensuring minimal transit times via tracked domestic carriers.

Investigators ready to proceed with experimental trials can directly order 10 mg vials of PT-141 through our secure procurement system, complete with instant access to downloadable HPLC and ESI-MS lot certificates.